中國人民保險集團(01339.HK):選舉第四屆董事會成員
格隆匯 3 月 23日丨中國人民保險集團(01339.HK)公佈,公司董事會於2021年3月23日以現場方式召開。依董事會會議通過之決議,董事會提名羅熹、王廷科、謝一羣和李祝用為公司第四屆董事會執行董事候選人,王清劍、苗福生、王少羣、喻強和王智斌為公司第四屆董事會非執行董事候選人,邵善波、高永文、徐麗娜、崔歷和陳武朝為公司第四屆董事會獨立非執行董事候選人。除了喻強、徐麗娜和崔歷外,上述董事候選人均為現任董事。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.